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1 This is a book about the industrial development of pharmaceutical 
production in Sub-Saharan Africa. Yet the values that drive this indus-
trial enquiry are rooted in the needs of a subcontinent with the worst 
health status in the world. The central argument of this book is that 
industrial development in pharmaceuticals and the capabilities it gener-
ates are necessary elements in African initiatives to tackle these acute 
health care needs. A successful pharmaceutical industry is no guar-
antor of good health care: India indeed has managed to grow a highly 
successful industry while leaving many of its people without access 
to competent care. However, without the technological, industrial, 
intellectual, organizational and research-related capabilities associated 
with competent pharmaceutical production, the African subcontinent 
cannot generate the resources to tackle the needs and demands of its 
population. 
 The book is a collective endeavour, by a group of editors and authors 
with a strong African and more broadly Southern presence, to find ways 
forward that link technological development, investment and industrial 
growth in pharmaceuticals to improving access to essential good-quality 
medicines, as part of moving towards universal access to competent 
health care. This book presents original research, much of it from 
recent fieldwork in African contexts. The authors include academics, 
researchers and practitioners, including some who have been or are 
currently managing pharmaceutical firms in African contexts, and some 
deeply involved in policy formulation and implementation. We aim to 
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shift the emphasis in international debate towards much more atten-
tion to the scope for sustained Africa-based and African-led initiatives to 
tackle this huge challenge. 
 In this we are contributing to a shift in mind-set that is already under 
way. African governments are increasingly considering medicines supply 
as a national security issue. African Heads of States have adopted the 
African Union’s Pharmaceutical Manufacturing Plan for Africa (African 
Union, 2007), and regional African bodies are taking similar initia-
tives. There has also been a sharp shift in approach amongst UN agen-
cies, including WHO and UNAIDS, from earlier critical stances towards 
support for the development of health sector manufacturing of medi-
cines and supplies in Africa (Sidibé et al., 2014). That shift in turn has 
built on work by UNIDO with African governments and the African 
Union (e.g. African Union 2012a 1 ; UNIDO, 2010; UNIDO/GoT, 2012). 
Bilateral donors, notably German and Japanese, are actively supporting 
upgrading in health-related industries. 
 The book’s roots are in historical political economy. The process of 
building – or failing to build – industrial strengths and industry-health 
system synergies is long term, as the complex 30-year trajectory of 
Brazil’s health-industrial complex illustrates. The book starts by chal-
lenging a highly persistent international myth: that Sub-Saharan Africa 
has no pharmaceutical industry. On the contrary, the industry has a 
long history and is strongly embedded in a number of African countries. 
Operating in a relatively high-skill, high-technology sector, pharmaceu-
tical firms have faced all the well-known challenges of African coun-
tries’ infrastructural weakness, in skills, utilities and transport, but many 
have built successful businesses and are investing in technological and 
product upgrading. Regional inter-country trade is expanding, and new 
investment opportunities are opening up. 
 The big challenges are twofold 
 First, there is the fight to sustain this industrialization effort in the 
current global market context – which is much more constraining to new 
competitors than the market context facing, for example, India in the 
years when it was building its pharmaceutical success story. Multilateral 
and bilateral policies have reinforced the stringent competition faced 
by Africa-based medicines producers. A core concept in our analysis is 
industrial capabilities. In Part I we explore the sources of the organi-
zational, institutional, technical and human capabilities to make good 
products, to compete profitably in globalized markets that constantly 
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force firms to upgrade, to overcome barriers to market entry and to 
distribute products effectively. 
 The second challenge is to ensure that the skills and competence 
built up by the manufacturers and distributors actually feed into better 
health care access for African populations. The institutional capabili-
ties of the health system need also to be built up, to support, buy and 
use effectively locally manufactured supplies. Only on that basis can 
governments generate policies that bring the interests of the industrial 
and health sectors closer together, to collaborate for mutual benefit. In 
Part II we examine some country experiences of health-industry inter-
actions, comparing East African countries’ experience with Brazil and 
India, arguing that health system structure and initiative are as impor-
tant as industrial policy to successful linkage. The values that underpin 
the importance of the pharmaceutical sector, its claim to policy priority, 
are rooted in the ethical requirement of universal access to competent 
health care. 
 The chapters in Part III therefore tease out experiences of some of 
the key aspects of health-industry interactions in more detail and 
identify some important policy issues to be tackled. All these issues 
are framed by political economy considerations of the ethics, inter-
ests and institutions involved. They include the highly contentious 
matters of price controls and standard setting for pharmaceutical 
products, plus examination of sources and problems of financing, the 
scope for innovative procurement processes that can reflect health 
system values while providing incentives for industrial investment, 
and the contested but important role of industrial manufacturers’ 
associations and political lobbying. 
 This book is a loud challenge to pessimism about African industrial 
development and health care commitment. African governments have 
responsibility for their populations’ health needs, and cannot address 
them without industrial expertise. The book explores the  conditions 
under which industrial improvement can benefit those who need access 
to medicines and health care, pulling together the arguments for access 
and distribution with those for investment and industrial development. 
There are different routes by which improving supply capacities can 
generate local health improvement: this book is about how to generate 
local paths that work. It also identifies ways in which international 
donors and policy makers can shift from impeding to supporting the 
long-term development of local industrial and health system capabili-
ties in African countries. 
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 1 .  See also  http://www.local-pharma-production.net/index.php?id=97 . 
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